3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
103
Lung Neoplasms
39
Neoplasms
11
Neoplasm Metastasis
11
Colorectal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Pancreatic Neoplasms
6
Mesothelioma, Malignant
5
Mesothelioma
5
Carcinoma
5
Ovarian Neoplasms
4
Meningeal Carcinomatosis
4
Melanoma
4
Colonic Neoplasms
4
Advanced Solid Tumors
4
Rectal Neoplasms
3
Adenocarcinoma of Lung
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Lung Diseases
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Brain Neoplasms
2
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Pemetrexed
×
90 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled